查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1611170

HIV 臨床試驗市場規模、佔有率、趨勢分析報告：按階段、試驗設計、申辦者、地區、細分市場預測，2025-2030 年

HIV Clinical Trials Market Size, Share & Trends Analysis Report By Phase, By Study Design, By Sponsor, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

HIV 臨床試驗市場成長與趨勢

Grand View Research, Inc.最新報告顯示，預計到2030年，全球HIV臨床試驗市場規模將達到21.1億美元，2025年至2030年複合年成長率為5.8%。該市場的主要促進因素是愛滋病毒疫苗臨床試驗數量的增加、愛滋病毒臨床試驗研發活動的增加以及對愛滋病毒感染的認知不斷提高，從而導致參與臨床試驗的患者數量不斷增加。在 COVID-19 大流行期間，市場成長停止。

HIV/愛滋病臨床試驗數量的下降是由於政府為預防 COVID-19 而實施的居家令，導致臨床試驗取消和延遲。它還包括患者招募的中斷、臨床試驗進行的障礙以及快速研究開發疫苗和藥物以預防在 HIV 臨床試驗中產生有害影響的 COVID-19。然而，透過臨床實驗試驗中心、監管機構和政府機構採取的策略措施，這些影響已大大減少。

據世界衛生組織稱，2020 年約有 3,770 萬人感染愛滋病毒。為了減少這一數字，生物技術和製藥公司正在增加資金和合作夥伴關係。此外，各國政府正在加強努力尋找治療方法並傳播對該疾病的認知。例如，2021 年 10 月，Samsung BioLogics 與 Enzolytics Inc. 合作。該合作旨在生產抗 HIV 和抗 SARS-CoV-2 單株抗體療法。

然而，缺乏對愛滋病毒臨床研究試驗和預防治療方法的認知是阻礙該市場成長的因素。根據 BioMed Central Ltd. 的歐洲報告，在 467 名參與者中，大約三分之一的人不知道自己感染了愛滋病毒。因此，對該疾病的無知和缺乏認知可能會阻礙愛滋病毒臨床試驗的參與。

HIV 臨床試驗市場報告亮點

  • 2024年，III期在HIV臨床試驗產業佔據主導地位，佔銷售佔有率的30.0%。 I 期試驗有助於評估藥物在不同劑量水平下的安全性和毒性，並確定藥物的藥物動力學。
  • 2024年，介入試驗領域在HIV臨床試驗產業中佔據主導地位，佔銷售佔有率的69.8%。
  • 2024年，製藥和生物製藥公司細分市場佔據最大市場佔有率。
  • 北美HIV臨床試驗市場主導全球市場，2024年佔最大佔有率，達47.3%。這是由於該地區正在進行的愛滋病毒臨床試驗數量增加。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章 HIV 臨床試驗市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 市場分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第4章 HIV 臨床試驗市場：階段、估計與趨勢分析

  • 細分儀表板
  • 全球愛滋病毒臨床試驗市場：相變分析
  • 2018-2030年全球HIV臨床試驗規模及趨勢分析（分階段）
  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第5章 HIV 臨床試驗市場：試驗設計、評估與趨勢分析

  • 細分儀表板
  • 全球愛滋病毒臨床試驗市場：研究設計變異分析
  • 2018-2030年全球HIV臨床試驗規模及趨勢分析（依試驗設計）
  • 干預試驗
  • 觀察測試
  • 擴大訪問考試

第6章 HIV 臨床試驗市場：申辦者、估算與趨勢分析

  • 細分儀表板
  • 全球愛滋病毒臨床試驗市場：申辦者變異分析
  • 2018-2030年全球HIV臨床試驗規模及趨勢分析（依申辦單位）
  • 製藥和生物製藥公司
  • 非營利組織
  • 其他

第7章 HIV 臨床試驗市場：區域估計與趨勢分析

  • 2024 年及 2030 年按地區分類的市場佔有率分析
  • 區域市場儀表板
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 公司分類
  • 2024 年企業市場分析
  • 公司簡介
    • PPD Inc.
    • IQVIA Inc.
    • Parexel International Corporation
    • ICON plc
    • Syneos Health
    • WuXi AppTec
    • Janssen Global Services, LLC
    • Gilead Sciences, Inc.
    • Bionor Holding AS
    • Charles River Laboratories
    • GSK plc.
    • SGS SA
Product Code: GVR-4-68039-955-8

HIV Clinical Trials Market Growth & Trends:

The global HIV clinical trials market size is estimated to reach USD 2.11 billion by 2030, registering to grow at a CAGR of 5.8% from 2025 to 2030 according to a new report by Grand View Research, Inc. The main drivers of this market are increasing HIV vaccine trials, increased R&D activities for HIV clinical trials, and rising HIV infection awareness, which leads to a large number of patients enrolling in clinical trials. During the COVID-19 pandemic, there was a halt in the market growth.

This decrease in HIV and AIDS clinical trials is due to stay-at-home orders by the government to prevent COVID-19 that led to canceled and delayed trials. It also includes disruption in patient recruitment, hurdles in the conduction of clinical trials, and rapid study for the development of vaccines and medical products for the prevention of COVID-19 that lead to detrimental effects in HIV clinical trial studies. However, these impacts were significantly reduced by adopting strategic measures taken by the clinical trial conducting organization, regulatory authorities, and government bodies.

According to the WHO, in 2020, there were around 37.7 million people infected with HIV infection. To reduce this number, increasing funding and partnerships by biotechnology and pharmaceutical firms have been observed. Moreover, increasing initiatives are being taken by the government to find treatment and spread awareness regarding this disease. For instance, in October 2021, Samsung BioLogics collaborated with Enzolytics Inc. This partnership aims to manufacture Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies.

However, a lack of awareness regarding HIV clinical research trials and the availability of treatments for preventing it are factors that are hindering the growth of this market. According to a report by BioMed Central Ltd. in Europe, out of 467 participants, about one-third of them were not aware of the HIV infection. As a result, ignorance and unawareness regarding the disease will prevent admission to an HIV clinical trial.

HIV Clinical Trials Market Report Highlights:

  • In 2024, the phase III segment dominated the HIV clinical trials industry, accounting for a revenue share of 30.0%. Phase I studies help to assess the drug's safety & toxicity at different levels of dose & determine drug pharmacokinetics.
  • In 2024, the interventional studies segment dominated the HIV clinical trials industry, accounting for a revenue share of 69.8%.
  • The pharmaceutical and biopharmaceutical companies segment accounted for the largest market share in 2024.
  • North America HIV clinical trials market dominated the global market in 2024 with the largest share of 47.3%. This can be attributed to the increased number of HIV clinical trials being conducted in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis
    • 1.6.2. Bottom-up Approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. HIV Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising drug approvals and new product launches
      • 3.2.1.2. Increasing R&D initiatives by biotechnology & pharmaceutical companies
      • 3.2.1.3. Increasing incidence of HIV
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Lack of awareness and access to treatment for HIV Infection
      • 3.2.2.2. Stringent regulations
  • 3.3. Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. HIV Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global HIV Clinical Trials Market: Phase Movement Analysis
  • 4.3. Global HIV Clinical Trials Size & Trend Analysis: by Phase, 2018 to 2030 (USD Million)
  • 4.4. Phase I
    • 4.4.1. Phase I market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Phase II
    • 4.5.1. Phase II market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Phase III
    • 4.6.1. Phase III market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Phase IV
    • 4.7.1. Phase IV market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. HIV Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global HIV Clinical Trials Market: Study Design Movement Analysis
  • 5.3. Global HIV Clinical Trials Size & Trend Analysis, by Study Design, 2018 to 2030 (USD Million)
  • 5.4. Interventional Studies
    • 5.4.1. Interventional studies market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Observational Studies
    • 5.5.1. Observational studies market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Expanded Access Studies
    • 5.6.1. Expanded access studies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. HIV Clinical Trials Market: Sponsor Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global HIV Clinical Trials Market: Sponsor Movement Analysis
  • 6.3. Global HIV Clinical Trials Size & Trend Analysis, by Sponsor, 2018 to 2030 (USD Million)
  • 6.4. Pharmaceutical & Biopharmaceutical Companies
    • 6.4.1. Pharmaceutical & biopharmaceutical companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Non-Profit Organizations
    • 6.5.1. Non-profit organizations market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. HIV Clinical Trials Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. North America
    • 7.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Competitive scenario
      • 7.3.2.3. Regulatory framework
      • 7.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Competitive scenario
      • 7.3.3.3. Regulatory framework
      • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key country dynamics
      • 7.3.4.2. Competitive scenario
      • 7.3.4.3. Regulatory framework
      • 7.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Competitive scenario
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Competitive scenario
      • 7.4.5.3. Regulatory framework
      • 7.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Competitive scenario
      • 7.4.6.3. Regulatory framework
      • 7.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Competitive scenario
      • 7.4.7.3. Regulatory framework
      • 7.4.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Competitive scenario
      • 7.4.8.3. Regulatory framework
      • 7.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key country dynamics
      • 7.4.9.2. Competitive scenario
      • 7.4.9.3. Regulatory framework
      • 7.4.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.7. Thailand
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.7.2.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Competitive scenario
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Competitive scenario
      • 7.7.5.3. Regulatory framework
      • 7.7.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Company Market Position Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. PPD Inc.
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Service benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. IQVIA Inc.
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Service benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Parexel International Corporation.
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Service benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. ICON plc
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Service benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Syneos Health
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Service benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. WuXi AppTec
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Service benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Janssen Global Services, LLC
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Service benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Gilead Sciences, Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Service benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Bionor Holding AS
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Service benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Charles River Laboratories
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Service benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. GSK plc.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Service benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. SGS SA
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Service benchmarking
      • 8.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of Tables
  • Table 2 List of Secondary Sources
  • Table 3 List of Abbreviations
  • Table 4 Global HIV Clinical Trials, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 5 Global HIV Clinical Trials, by Services Type, 2018 - 2030 (USD Million)
  • Table 6 Global HIV Clinical Trials, by Region, 2018 - 2030 (USD Million)
  • Table 7 North America HIV Clinical Trials, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 9 North America HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 10 North America HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 11 U.S. HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 12 U.S. HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 13 U.S. HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 14 Canada HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 15 Canada HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 16 Canada HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 17 Mexico HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 18 Mexico HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 19 Mexico HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 20 Europe HIV Clinical Trials, by Country, 2018 - 2030 (USD Million)
  • Table 21 Europe HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 22 Europe HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 23 Europe HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 24 UK HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 25 UK HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 26 UK HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 27 Germany HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 28 Germany HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 29 Germany HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 30 France HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 31 France HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 32 France HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 33 Italy HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 34 Italy HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 35 Italy HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 36 Spain HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 37 Spain HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 38 Spain HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 39 Denmark HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 40 Denmark HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 41 Denmark HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 42 Sweden HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 43 Sweden HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 44 Sweden HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 45 Norway HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 46 Norway HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 47 Norway HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific HIV Clinical Trials, by Country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 52 Japan HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 53 Japan HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 54 Japan HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 55 China HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 56 China HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 57 China HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 58 Japan HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 59 Japan HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 60 Japan HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 61 China HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 62 China HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 63 China HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 64 India HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 65 India HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 66 India HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 67 Thailand HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 68 Thailand HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 69 Thailand HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 70 South Korea HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 71 South Korea HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 72 South Korea HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 73 Australia HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 74 Australia HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 75 Australia HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 76 Latin America HIV Clinical Trials, by Country, 2018 - 2030 (USD Million)
  • Table 77 Latin America HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 78 Latin America HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 79 Latin America HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 80 Brazil HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 81 Brazil HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 82 Brazil HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 83 Argentina HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 84 Argentina HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 85 Argentina HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 86 Middle East & Africa HIV Clinical Trials, by Country, 2018 - 2030 (USD Million)
  • Table 87 Middle East & Africa HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 88 Middle East & Africa HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 89 Middle East & Africa HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 90 South Africa HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 91 South Africa HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 92 South Africa HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 93 Saudi Arabia HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 94 Saudi Arabia HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 95 Saudi Arabia HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 96 UAE HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 97 UAE HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 98 UAE HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)
  • Table 99 Kuwait HIV Clinical Trials, by Phase, 2018 - 2030 (USD Million)
  • Table 100 Kuwait HIV Clinical Trials, by Study Design, 2018 - 2030 (USD Million)
  • Table 101 Kuwait HIV Clinical Trials, by Sponsor, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 HIV Clinical Trials Market revenue, 2018 - 2030 (USD Million)
  • Fig. 10 HIV Clinical Trials Market snapshot
  • Fig. 11 HIV Clinical Trials Market driver impact
  • Fig. 12 HIV Clinical Trials Market restraint impact
  • Fig. 13 HIV Clinical Trials Market: Phase takeaways (USD Million)
  • Fig. 14 HIV Clinical Trials Market: Phase movement analysis
  • Fig. 15 Phase I market, 2018 - 2030 (USD Million)
  • Fig. 16 Phase II market, 2018 - 2030 (USD Million)
  • Fig. 17 Phase III market, 2018 - 2030 (USD Million)
  • Fig. 18 Phase IV market, 2018 - 2030 (USD Million)
  • Fig. 19 HIV Clinical Trials Market: Study design takeaways (USD Million)
  • Fig. 20 HIV Clinical Trials Market: Study design movement analysis
  • Fig. 21 Interventional studies market, 2018 - 2030 (USD Million)
  • Fig. 22 Observational studies market, 2018 - 2030 (USD Million)
  • Fig. 23 Expanded access studies market, 2018 - 2030 (USD Million)
  • Fig. 24 HIV Clinical Trials Market: Sponsor takeaways (USD Million)
  • Fig. 25 HIV Clinical Trials Market: Sponsor movement analysis
  • Fig. 26 Pharmaceutical & biopharmaceutical companies' market, 2018 - 2030 (USD Million)
  • Fig. 27 Non-profit organizations market, 2018 - 2030 (USD Million)
  • Fig. 28 Others market, 2018 - 2030 (USD Million)
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 Regional outlook, 2024 & 2030
  • Fig. 31 North America HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 33 Canada HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 34 Mexico HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 35 Europe HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 36 UK HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 37 Germany HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 38 France HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 39 Italy HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 40 Spain companion animal Health market, 2018 - 2030 (USD Million)
  • Fig. 41 Sweden HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 42 Denmark HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 43 Norway HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 44 Asia Pacific HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 45 Japan HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 46 China HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 47 India HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 48 Thailand HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 49 South Korea HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 50 Australia HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 51 Latin America HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 52 Brazil HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 53 Argentina HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 54 Middle East & Africa HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 55 South Africa HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 56 Saudi Arabia HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 57 UAE HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 58 Kuwait HIV Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 59 Market participant categorization